查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362984

抗體合約開發和製造組織市場規模、佔有率和趨勢分析報告：按產品、來源、治療領域、最終用途、地區和細分市場進行預測，2023-2030 年

Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

抗體 CDMO（抗體合約開發和製造組織）市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，預計2023年至2030年全球抗體CDMO市場將以14.0%的年複合成長率成長，2030年將達到584億美元。

新型抗體療法的研發活動不斷增加、癌症患者數量不斷增加以及合約開發和受託製造廠商(CDMO) 與生物製藥公司之間的合作不斷增加，是推動抗體 CDMO 市場成長的關鍵要素。

抗體是藥物療法，尤其用於癌症治療。這些抗體不會影響體內的健康細胞，並提高了藥物的治療指數。這是癌症治療中對抗體有大量需求的兩個主要原因。這些要素支持臨床研究中抗體藥物複合體(ADC) 等抗體類型的開發。

由於抗體在癌症治療中的高效性，生物製藥公司獲得了大量資金來進行抗體相關研究。例如，2022年10月，Mablink Bioscience籌集了3,100萬美元A輪資金籌措，用於建立用於癌症治療的抗體ADC管道。同樣，2021年7月，ProfoundBio從投資者那裡獲得了5500萬美元，以加速其抗體ADC管道的開發。因此，生物製藥公司加大配合措施開發與癌症治療相關的新療法是支持市場成長的主要要素之一。

COVID-19大流行對市場產生了重大影響。然而，一些公司已採取合作、合併和收購等內部策略舉措，以減輕疫情的影響，從而恢復銷售收益。此外，烏克蘭和俄羅斯之間的地緣政治戰爭也對抗體 CDMO 市場產生了負面影響。這對美國等某些國家產生了重大影響，導致2022年全球市場整體收益適度下降。

抗體 CDMO 市場報告亮點

  • 單株抗體細分市場佔比最大，2022年將達67.6%。這個細分市場是由對基於抗癌的單株抗體療法不斷成長的需求推動的，並結構了總抗體療法的很大一部分。
  • 從來源來看，哺乳動物細分市場所佔佔有率最大，到 2022 年將達到 58.5%。該細分市場的高佔有率主要是由於哺乳動物抗體療法的外包比例不斷增加。因此，CDMO 以比自家公司生產相對較低的成本提供製造服務，支撐了其龐大的市場佔有率。
  • 預計免疫介導疾病領域在預測期內將以 14.6% 的最快年複合成長率成長。這是由於旨在發現治療免疫介導疾病的新型抗體的臨床試驗所佔比例不斷增加。
  • 預計2023年至2030年生物製藥公司將以14.3%的最快年複合成長率成長。這是由於越來越多的生物製藥公司專注於生產新型抗體療法，支持預測期內的良好成長。
  • 預計亞太地區在預測期內將以 14.2% 的最高年複合成長率成長。高成長的主要原因是印度和中國等亞洲國家，這些國家的生產成本相對低於西方國家，從而吸引了全部區域更大的客戶群並支持了該地區的成長。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 抗體 CDMO 市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 抗體CDMO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析
    • 抗體研究的臨床試驗量分析，（2022）
    • 法規狀況：

第4章 抗體 CDMO 市場：產品估算與趨勢分析

  • 抗體 CDMO 市場，按產品：細分儀表板
  • 抗體 CDMO 市場（按產品）：波動分析

第5章 抗體 CDMO 市場：來源估算與趨勢分析

  • 抗體 CDMO 市場，資料來源：細分儀表板
  • 抗體 CDMO 市場，依來源：變異分析

第6章 抗體CDMO市場：治療領域預估及趨勢分析

  • 抗體 CDMO 市場，依治療領域：細分儀表板
  • 抗體 CDMO 市場（按治療領域）：波動分析

第7章 抗體 CDMO 市場：最終用途估計與趨勢分析

  • 抗體 CDMO 市場，依最終用途：細分儀表板
  • 抗體 CDMO 市場，依最終用途：變化分析

第8章 抗體 CDMO 市場：區域估算與趨勢分析

  • 2022 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興企業
    • 2022 年公司市場佔有率分析
  • 公司簡介
    • Lonza
    • Catalent, Inc
    • Samsung Biologics
    • WuXi Biologics
    • AGC Biologics
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Charles River Laboratories
    • FUJIFILM Holdings Corporation
    • mAbxience
Product Code: GVR-4-68040-116-7

Antibody CDMO Market Growth & Trends:

The global antibody CDMO market is expected to reach USD 58.40 billion by 2030, expanding at a CAGR of 14.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.

Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.

Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.

The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.

Antibody CDMO Market Report Highlights:

  • Monoclonal antibodies segment accounted for the largest share of 67.6% in 2022.The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics
  • Based on the source, the mammalian segment accounted for the largest share of 58.5% in 2022. High shares of the segment are majorly due to increasing rates of outsourcing witnessed across mammalian antibody therapeutics, as the cost of production of such antibodies is significantly high. Hence, CDMOs offer these manufacturing services at a comparatively lower cost than in-house production rates, thus supporting its large segment share in the market
  • The immune-mediated disorders segment is anticipated to register the fastest CAGR of 14.6% during the forecast period. This is due to the growing rate of clinical trials targeted at discovering novel antibodies in the treatment of immune-mediated disorders
  • Biopharmaceutical companies are anticipated to register the fastest CAGR of 14.3% from 2023 to 2030, owing increasing number of biopharmaceutical companies focusing on producing novel antibody therapeutics, thus supporting its lucrative growth during the forecast period
  • Asia Pacific is anticipated to witness the highest CAGR of 14.2% during the forecast time frame. High growth is majorly due to Asian countries such as India and China, where the cost of production is comparatively lower than in Western economies, thus attracting a larger customer base across the region and thereby supporting the region's growth

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Product
    • 1.1.3. Source
    • 1.1.4. Therapeutic Area
    • 1.1.5. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective-1
    • 1.4.2. Objective-2
    • 1.4.3. Objective-3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antibody CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Antibody CDMO Services
      • 3.2.1.2. Rising Incidence of Cancer
      • 3.2.1.3. High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing Contributing to Demand For Outsourcing Services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality Issues While Outsourcing
      • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
  • 3.3. Antibody CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
    • 3.3.4. Clinical Trial Volume Analysis for Antibody Research, (2022)
    • 3.3.5. Regulatory Landscape:
      • 3.3.5.1. U.S.
      • 3.3.5.2. Europe
      • 3.3.5.3. Asia Pacific
      • 3.3.5.4. Rest of the World

Chapter 4. Antibody CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Antibody CDMO Market, By Product: Segment Dashboard
  • 4.2. Antibody CDMO Market, By Product: Movement Analysis
  • 4.3. Antibody CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
    • 4.3.1. Monoclonal Antibodies
      • 4.3.1.1. Monoclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
    • 4.3.2. Polyclonal Antibodies
      • 4.3.2.1. Polyclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 5. Antibody CDMO Market: Source Estimates & Trend Analysis

  • 5.1. Antibody CDMO Market, By Source: Segment Dashboard
  • 5.2. Antibody CDMO Market, By Source: Movement Analysis
  • 5.3. Antibody CDMO Market Estimates & Forecasts, By Source, 2018 - 2030
    • 5.3.1. Mammalian
      • 5.3.1.1. Mammalian Antibody CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Microbial
      • 5.3.2.1. Microbial Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 6. Antibody CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Antibody CDMO Market, By Therapeutic Area: Segment Dashboard
  • 6.2. Antibody CDMO Market, By Therapeutic Area: Movement Analysis
  • 6.3. Antibody CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
    • 6.3.1. Oncology
      • 6.3.1.1. Oncology Antibody CDMO Market 2018 to 2030 (USD Million)
    • 6.3.2. Neurology
      • 6.3.2.1. Neurology Antibody CDMO Market 2018 to 2030 (USD Million)
    • 6.3.3. Cardiology
      • 6.3.3.1. Cardiology Antibody CDMO Market 2018 to 2030 (USD Million)
    • 6.3.4. Infectious Diseases
      • 6.3.4.1. Infectious Diseases Antibody CDMO Market 2018 to 2030 (USD Million)
    • 6.3.5. Immune-mediated Disorders
      • 6.3.5.1. Immune-mediated Disorders Antibody CDMO Market 2018 to 2030 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Antibody CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Antibody CDMO Market, By End Use: Segment Dashboard
  • 7.2. Antibody CDMO Market, By End Use: Movement Analysis
  • 7.3. Antibody CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
    • 7.3.1. Biopharmaceutical Companies
      • 7.3.1.1. Biopharmaceutical Companies Antibody CDMO Market 2018 to 2030 (USD Million)
    • 7.3.2. Research Laboratories
      • 7.3.2.1. Research Laboratories Antibody CDMO Market 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 8. Antibody CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2022 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Competitive Scenario
      • 8.5.1.3. Regulatory Framework
      • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 8.5.2. Germany
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. France
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. Italy
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Spain
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Denmark
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Norway
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key Country Dynamics
      • 8.6.1.2. Competitive Scenario
      • 8.6.1.3. Regulatory Framework
      • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 8.6.2. India
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. South Korea
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. Thailand
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key Country Dynamics
      • 8.7.1.2. Competitive Scenario
      • 8.7.1.3. Regulatory Framework
      • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 8.7.2. Mexico
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key Country Dynamics
      • 8.8.1.2. Competitive Scenario
      • 8.8.1.3. Regulatory Framework
      • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. UAE
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. Kuwait
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
    • 9.1.4. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. Lonza
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Service Benchmarking
      • 9.2.1.4. Strategic Initiatives
    • 9.2.2. Catalent, Inc
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Service Benchmarking
      • 9.2.2.4. Strategic Initiatives
    • 9.2.3. Samsung Biologics
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Service Benchmarking
      • 9.2.3.4. Strategic Initiatives
    • 9.2.4. WuXi Biologics
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Service Benchmarking
      • 9.2.4.4. Strategic Initiatives
    • 9.2.5. AGC Biologics
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Financial Performance
      • 9.2.5.3. Service Benchmarking
      • 9.2.5.4. Strategic Initiatives
    • 9.2.6. AbbVie Inc.
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Service Benchmarking
      • 9.2.6.4. Strategic Initiatives
    • 9.2.7. Boehringer Ingelheim International GmbH
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Service Benchmarking
      • 9.2.7.4. Strategic Initiatives
    • 9.2.8. Charles River Laboratories
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Financial Performance
      • 9.2.8.3. Service Benchmarking
      • 9.2.8.4. Strategic Initiatives
    • 9.2.9. FUJIFILM Holdings Corporation
      • 9.2.9.1. Company Overview
      • 9.2.9.2. Financial Performance
      • 9.2.9.3. Service Benchmarking
      • 9.2.9.4. Strategic Initiatives
    • 9.2.10. mAbxience
      • 9.2.10.1. Company Overview
      • 9.2.10.2. Financial Performance
      • 9.2.10.3. Service Benchmarking
      • 9.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 5 North America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 6 North America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 7 North America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 9 U.S. Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 12 Canada Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 13 Canada Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Europe Antibody CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 18 Europe Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 21 UK Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 22 UK Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 23 UK Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 UK Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Germany Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 Germany Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 30 France Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 31 France Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 32 France Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Italy Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 34 Italy Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 36 Italy Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 38 Spain Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Spain Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 40 Spain Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Denmark Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 42 Denmark Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 44 Denmark Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Sweden Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 46 Sweden Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 47 Sweden Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 48 Sweden Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Norway Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 50 Norway Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Norway Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 52 Norway Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Antibody CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 58 China Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 59 China Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 60 China Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 61 China Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 62 Japan Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 63 Japan Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 64 Japan Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 Japan Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 India Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 67 India Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 68 India Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 69 India Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Australia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 71 Australia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Australia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 73 Australia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 South Korea Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 75 South Korea Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 76 South Korea Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 77 South Korea Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 78 Thailand Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 79 Thailand Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 80 Thailand Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 81 Thailand Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 82 Latin America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 83 Latin America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 84 Latin America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 Latin America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 86 Latin America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Brazil Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 88 Brazil Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Brazil Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 90 Brazil Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Mexico Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 92 Mexico Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 93 Mexico Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 94 Mexico Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Argentina Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 96 Argentina Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 97 Argentina Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 98 Argentina Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Antibody CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 104 South Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 105 South Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 106 South Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 107 South Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 112 UAE Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 113 UAE Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 114 UAE Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 115 UAE Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Competitive Landscape Snapshot
  • Fig. 16 Antibody CDMO market segmentation
  • Fig. 17 Parent market outlook (2022)
  • Fig. 18 Related/ancillary market outlook (2022)
  • Fig. 19 Market driver relevance analysis (Current & future impact)
  • Fig. 20 Market restraint relevance analysis (Current & future impact)
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 23 Antibody CDMO Market Product outlook: Segment dashboard
  • Fig. 24 Antibody CDMO :Product movement analysis
  • Fig. 25 Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 26 Polyclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 27 Others Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 28 Antibody CDMO Market Source outlook: Segment dashboard
  • Fig. 29 Antibody CDMO : Source type movement analysis
  • Fig. 30 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 31 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 32 Antibody CDMO market Therapeutic Area outlook: Segment dashboard
  • Fig. 33 Antibody CDMO market: Therapeutic Area movement analysis
  • Fig. 34 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 35 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 36 Cardiology market, 2018 - 2030 (USD Million)
  • Fig. 37 Infectious Diseases market, 2018 - 2030 (USD Million)
  • Fig. 38 Immune-mediated Disorders market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional marketplace: Segment dashboard
  • Fig. 41 Regional outlook, 2022 & 2030
  • Fig. 42 North America market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany market, 2018 - 2030 (USD Million)
  • Fig. 47 UK market, 2018 - 2030 (USD Million)
  • Fig. 48 France market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark market, 2018 - 2030(USD Million)
  • Fig. 52 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 55 China market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan market, 2018 - 2030 (USD Million)
  • Fig. 57 India market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia market, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait market, 2018 - 2030 (USD Million)